BioLargo (BLGO) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	13-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	BIOLARGO, INC.
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		83,322,039
Amendment Flag	FALSE
Entity Central Index Key	880242
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$227,441	$154,460
Accounts receivable, net of allowance	7,431	5,617
Prepaid assets	45,000	45,000
Inventory	20,515	25,514
Total current assets	300,387	230,591
Other Assets, net of amortization	27,347	30,077
Deferred financing fees, net of amortization	55,417
TOTAL ASSETS	383,151	260,668
CURRENT LIABILITIES
Accounts payable and accrued expenses	512,124	494,938
Notes and convertible notes payable	383,000	250,000
Discount on convertible notes payable	-258,071	-192,000
Deferred grant revenue	4,141
Deposits	150,000	100,000
Total current liabilities	791,194	652,938
LONG-TERM LIABILITIES
Convertible note payable, net of current portion	230,000
Discount on convertible note payable, net of current portion	-224,351
Total long-term liabilities	5,649
TOTAL LIABILITIES	835,188	652,938
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY (DEFICIT)
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2014 and March 31, 2015.
Common Stock, $.00067 Par Value, 200,000,000 Shares Authorized, 82,909,300 and 83,322,039 Shares Issued and Outstanding, at December 31, 2014 and March 31, 2015.	55,570	55,293
Additional paid-in capital	79,282,064	78,511,529
Accumulated deficit	-79,794,105	-79,019,719
Noncontrolling interest	54,871	60,627
Total stockholders’ equity (deficit)	-413,692	-392,270
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$383,151	$260,668

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Convertible Preferred Stock, Par Value (in Dollars per share)	$0.00	$0.00
Convertible Preferred Stock, Shares Authorized	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued	0	0
Convertible Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares Issued	83,322,039	82,909,300
Common Stock, Shares Outstanding	83,322,039	82,909,300

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Product revenue	$13,875	$9,287
Grant revenue	12,796
Total revenue	26,671	9,287
Cost of goods sold	6,381	2,530
Gross margin	20,290	6,757
Costs and expenses
Selling, general and administrative	560,525	607,366
Research and development	137,999	163,605
Amortization and depreciation	2,730	2,730
Total costs and expenses	701,254	773,701
Loss from operations	-680,964	-766,944
Interest expense	-105,224	-306,126
Net loss	-786,188	-1,073,070
Net loss from our noncontrolling interests	-5,756	-53,684
Net loss attributable to our common stockholders	($780,432)	($1,019,386)
Loss per common share – basic and diluted (in Dollars per share)	($0.01)	($0.01)
Weighted average common share equivalents outstanding (in Shares)	82,973,744	76,409,578

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (USD $)	Exchange for Clyra Shares [Member]	Exchange for Clyra Shares [Member]	Issued as Discount [Member]	Issued as Discount [Member]	Issued as Fees [Member]	Issued as Fees [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Third-Party Vendors [Member]	Officers [Member]	Officers and Board of Directors [Member]	Total
	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]		Additional Paid-in Capital [Member]		Third-Party Vendors [Member]	Officers [Member]		Third-Party Vendors [Member]	Officers [Member]	Officers and Board of Directors [Member]
Balance at Dec. 31, 2014									$55,293				$78,511,529	($79,019,719)	$60,627				($392,270)
Shares (in Shares) at Dec. 31, 2014									82,909,300
Issuance of stock in exchange of Clyra shares	67	-67
Issuance of stock in exchange of Clyra shares (in Shares)	100,000
Issuance of stock for non-employee services							21	189		10,704	99,913					10,725	100,102
Issuance of stock for non-employee services (in Shares)							30,761	281,978
Issuance of stock for services										156,625		99,000				156,625		99,000
Fair value of warrant			363,000	363,000	41,360	41,360
Net loss														-780,432	-5,756				-786,188
Balance at Mar. 31, 2015									$55,570				$79,794,105	($79,800,151)	$54,871				($413,692)
Shares (in Shares) at Mar. 31, 2015									83,322,039

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	($786,188)	($1,073,070)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense	72,578	244,800
Amortization expense	2,730	2,730
Increase (decrease) in cash from change in:
Accounts receivable	-1,814	-458
Inventory	4,999	-3,869
Prepaid expenses		-45,000
Deposits	50,000	100,000
Accounts payable and accrued expenses	12,596	-44,127
Deferred revenue	4,141
Net Cash Used In Operating Activities	-274,506	-556,564
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible notes payable	363,000
Payments of financing cost	-15,513
Proceeds from sale of stock		827,500
Net Cash Provided By Financing Activities	347,487	827,500
NET INCREASE IN CASH AND CASH EQUIVALENTS	72,981	270,936
CASH AND CASH EQUIVALENTS b BEGINNING	154,460	92,437
CASH AND CASH EQUIVALENTS b ENDING	227,441	363,373
Cash Paid During the Period for:
Interest	4,683
Taxes		400
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Fair value of warrants issued with convertible notes payable	363,000
Fair value of warrants issued as fees for convertible notes payable	41,360
Common Stock [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense		291,574
Warrant [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense	72,578
Accounts Payable [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Conversion of Payables	247,773	159,697
Officers and Board of Directors [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense related to options issued to our board of directors	99,000	89,961
Non-cash expense stock issued	100,102	10,720
Consultants [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense stock issued	10,725	48,225
Vendors [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense stock issued	156,625	66,750
Notes Payable, Other Payables [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Conversion of Payables		$584,800

Note_1_Business_and_Organizati

Note 1 - Business and Organization	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Business and Organization
	Outlook
	The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, we had a net loss of $786,188 for the three-month period ended March 31, 2015, and at March 31, 2015, we had negative working capital of $529,152, current assets of $300,387, and an accumulated stockholders’ deficit of $79,794,105. The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract significant new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technology. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
	We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Our total cash and cash equivalents were $227,441 at March 31, 2015. We had revenues of $26,671 in the three-month period ended March 31, 2015, which amount was not sufficient to fund our operations. We generally have not had enough cash or sources of capital to pay our accounts payable and expenses as they arise, and have relied on the issuance of stock options and common stock, as well as extended payment terms with our vendors, to continue to operate. We will be required to raise substantial additional capital to expand our operations, including without limitation, hiring additional personnel, additional scientific and third-party testing, costs associated with obtaining regulatory approvals and filing additional patent applications to protect our intellectual property, and possible strategic acquisitions or alliances, as well as to meet our liabilities as they become due for the next 12 months.
	As of March 31, 2015, we had $613,000 principal amount outstanding on our convertible note payables (see Note 5), and $512,124 of outstanding accounts payable. (See Note 10.)
	The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8-03 of Regulation S-X under the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for annual financial statements.  In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. For some of our activities, we are still operating in the early stages of the sales and distribution process, and therefore our operating results for the three-month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or for any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2015.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies
	Inventory
	Inventories are stated at the lower of cost or net realizable value using the average cost method.  Inventories consisted of:
			31-Dec-14		31-Mar-15
	Raw materials		$	18,816	$	18,875
	Finished goods (see Note 4)			6,698		1,640
	Total inventory		$	25,514	$	20,515
	Other Assets
	Other Assets consists of payments made to purchase patents related to our efforts in commercializing the ISAN system.
	For the three-month periods ended March 31, 2014 and 2015 we recorded amortization expense totaling $2,730 and $2,730, respectively.
	We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. No impairment has been recorded for the three-month period ended March 31, 2015.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, uncollectible accounts receivable, asset depreciation and amortization, and taxes, among others.
	Share-based Payments
	All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values.
	For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
	During the three-month periods ended March 31, 2014 and 2015 we recorded an aggregate $156,711 and $255,625 in selling general and administrative expense related to options issued outside of our 2007 Equity Incentive Plan (see Note 9).
	During the three-month period ended March 31, 2014 we issued an aggregate 83,493 shares of our common stock to our corporate Secretary/President of our Odor-No-More subsidiary in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $35,902. During the three-month period ended March 31, 2015 we issued an aggregate 281,978 shares of our common stock to our Chief Executive Officer, Chief Technology Officer and our corporate Secretary in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $100,102. (See Note 9).
	During the three-month periods ended March 31, 2014 and 2015 we issued an aggregate 161,980 and 30,761 shares of our common stock to third party vendors in lieu of accrued and unpaid obligations totaling $56,295 and $10,725, respectively. (See Note 9).
	Non-Cash Transactions
	We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
	The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
	Revenue Recognition
	Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property or in the form of a grant. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. Grants received are recognized as revenue when the terms and conditions of the grant are met on a periodic basis over the life of the grant.
	Earnings (Loss) Per Share
	We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three-month periods ended March 31, 2014 and 2015, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss.
	Deferred Financing Fees
	The Company has unamortized debt issuance costs related to its current convertible notes payable and long-term convertible notes payable. These costs are amortized over the life of the related debt and recorded as interest expense. For the three-month period ended March 31, 2015 we had a total of $56,873 of debt issuance costs and amortization totaled $1,456.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new, principle-based revenue recognition framework that will affect all revenue-generating activities. In addition to superseding and replacing nearly all existing revenue recognition guidance under U.S. GAAP, including industry-specific guidance, the new standard:
	•	changes the basis for deciding when revenue is recognized over time or at a point in time;
	•	provides new guidance on specific aspects of revenue recognition; and
	•	expands and improves disclosures about revenue.
	Entities are required to apply the standard for annual periods beginning after December 15, 2017, and for interim periods therein. The standard permits the use of either the retrospective method, where prior period results are reflected on a comparable basis, or cumulative effect method. Management is currently evaluating the effect of this pronouncement on its financial reporting.
	In August 2014, the FASB issued ASU No. 2014-15 ("ASU 2014-15"), Presentation of Financial Statements-Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires a Company's management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its consolidated financial statements.

Note_3_Deposit

Note 3 - Deposit	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Deposit Liabilities Disclosures [Text Block]	Note 3. Deposits
	Customer
	In 2012, we executed a joint venture agreement with Peter Holdings Ltd., the principal funding source of the development of the Isan System, whereby we jointly purchased the intellectual property associated with the Isan System, and agreed to share any royalties from the intellectual property on an equal 50/50 basis. In February 2014, we received a deposit of $100,000 from InsulTech Manufacturing, LLC, an Arizona limited liability company d/b/a Clarion Water (“Clarion Water”) towards a worldwide, exclusive license of the Isan System. On August 12, 2014, we entered into a license agreement with Clarion Water in which we granted an exclusive license to commercialize the Isan System. The license agreement provides that the $100,000 deposit is non-refundable, and is to be credited to future payments of royalties or sublicense fees due under the license agreement. The agreement further provides for a 10% royalty of licensee’s “net sales revenue”, and 40% of sublicensing fees. Licensee is required to make minimum payments beginning July 1, 2016, of $50,000 per quarter, and we are obligated to share any revenues under the agreement on an equal basis with Peter Holdings Pty. Ltd. The intellectual property subject to the license agreement includes all intellectual property related to the Isan System, including all patents, trademarks, proprietary knowledge, and other similar know-how or rights relating to or arising out of the Isan System or the patents related to the Isan System. The agreement contains other terms and conditions typically found in intellectual property license agreements.
	Investor
	On March 27, 2015, we received $50,000 from a potential investor in our 2015 Unit Offering. We did not receive a subscription agreement from that individual until after March 31, 2015, and thus we recorded this amount as a deposit until we received the executed documents.

Note_4_Private_Securities_Offe

Note 4 - Private Securities Offerings	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 4. Private Securities Offerings
	Summer 2013 Private Securities Offering
	Pursuant to a private offering of our common stock at a price of $0.25 per share that commenced June 2013, through its expiration on March 31, 2014, we sold 3,370,000 shares of our common stock to 23 accredited investors and received $842,500 gross and $837,000 net proceeds from the sales. Of the aggregate 3,370,000 shares sold in the offering, for the three-month period ended March 31, 2104, we sold 3,110,000 shares of our common stock and received $777,500 gross proceeds from the sales. Fees related to this offering consisted of $5,500 cash payments, and an additional $47,100 in fees were issued in shares of our common stock.
	Each purchaser of stock received, for no additional consideration, a stock purchase warrant which entitles the holder to purchase a number of additional shares of our common stock equal to the number of shares originally purchased. The warrant is exercisable at $0.30 per share, will expire on December 31, 2016, and is subject to a call provision in the event BioLargo’s common stock price reaches $0.60 per share over a period of 40 days.
	Clyra Spring 2014 Private Securities Offering
	On February 1, 2014, our subsidiary Clyra (see Note 11) began a private securities offering, selling up to 1,000 shares of its common stock at $1,000 per share. On March 14, 2014, Clyra sold 50 shares of its common stock to one accredited investor and received $50,000 gross and net proceeds from the sale.
	Each purchaser of stock received, for no additional consideration, (i) a stock purchase warrant entitling the holder to purchase the same number of shares of Clyra common stock as purchased in the offering for $1,833.33 per share until July 30, 2015, and (ii) a warrant issued by BioLargo that allows the holder to exchange one share of Clyra common stock for 4,000 shares of BioLargo common stock, until July 30, 2015.
	2015 Unit Offering
	On January 15, 2015, we commenced a private securities offering of “units”, each Unit consisting of a convertible promissory note and “Series A” stock purchase warrant. The price and availability of the Units are set forth in a “pricing supplement” issued from time-to-time, and priced up to a 30% discount to the market price of the Company’s common stock. The Offering is subject to an over-allotment of 20%, or an additional $1,000,000 in Units, for an aggregate total of $6,000,000, and shall be known as the Company’s 2015 “Unit Offering.” The Company has the right to register the common shares underlying the notes and warrants (“Shares”) with the Securities and Exchange Commission, and the obligation to register the Shares in the event gross proceeds of $3,000,000 are raised in the Offering.
	Purchasers of the Units will receive an unsecured convertible promissory note bearing interest at the rate of 12% per annum on the amount invested. Any interest due will be paid quarterly in arrears in cash or shares of common stock. If paid by the issuance of common stock, interest is paid at a conversion price equal to the average closing price of the Company’s common stock over the 20 trading days prior to the interest payment due date. The principal amount of the note may be paid by the issuance of shares of common stock, or cash, upon maturity at the Company’s election. When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the Unit price, as it is established at the time of the original investment by the applicable Pricing Supplement. Notes may be converted at any time by the investor, at maturity by the Company, or by the Company prior to maturity, so long as all of the following conditions are met: (i) the Shares issued as payment are registered with the SEC, (ii) the Company’s common stock closes for ten consecutive trading days at or above three times the Unit price. Notes mature on June 1, 2018.
	In addition to the convertible promissory note, each investor will receive a “Series A Warrant” allowing for the purchase of the number of common shares equal to the investment amount divided by the Unit price, (e.g., one warrant share for each share of common stock which the investor is eligible to receive through conversion of his original convertible note) and, the warrant will have an exercise price as set forth in the pricing supplement. Each Series A Warrant expires June 1, 2020. The Company may “call” the Series A Warrant, requiring the investor to exercise the warrant within 30 days or forever lose the rights to do so, only if the following conditions have been met: (i) the underlying Shares are registered with the SEC, and (ii) the Company’s common stock closes for 10 consecutive trading days at or above two times the exercise price.
	See Note 5 for details on Units sold in the three-month period ended March 31, 2015. See also Note 13, Subsequent Events.

Note_5_Notes_and_Convertible_N

Note 5 - Notes and Convertible Notes Payable	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Short-term Debt [Text Block]	Note 5. Notes and Convertible Notes Payable
	2015 Unit Offering
	In accordance with the terms of our 2015 Unit Offering (see Note 4), during the three-month period ended March 31, 2015, we received $230,000 and issued unsecured convertible promissory notes with a maturity date of June 1, 2018, which accrue interest at a rate of 12% per annum. Each investor, for no additional consideration, received a stock purchase warrant exercisable at $0.40 per share, which expires June 1, 2020. We issued warrants to purchase an aggregate 1,023,400 shares to investors and for commissions. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in a $230,000 discount on the convertible note payables.
	December/January Notes
	In January 2015, we received $133,000 and issued unsecured convertible promissory notes each with a one-year maturity date, which accrue interest at a rate of 12% per annum. Each noteholder, for no additional consideration, received a stock purchase warrant exercisable at $0.30 per share, which terminates three year after the date of issuance. We issued warrants to purchase an aggregate 266,000 shares. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in a $133,000 discount on the convertible note payables. Each noteholder may exchange the note for the securities offered in our current private securities offering.
	In December 2014, we received $200,000 and issued unsecured convertible promissory notes each with a one-year maturity date, which accrue interest at a rate of 12% per annum. Each noteholder, for no additional consideration, received a stock purchase warrant exercisable at $0.30 per share, which terminates three years after the date of issuance. We issued warrants to purchase an aggregate 350,000 shares. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in a $200,000 discount on the convertible note payables. Each noteholder may exchange the note for the securities offered in our current private securities offering. On April 27, 2015 a noteholder exchanged this note for a “unit” on the terms offered in our 2015 Unit Offering (see Note 4), such that the noteholder was issued a new convertible promissory note with an expiration date of June 1, 2018, and a stock purchase warrant to purchase 226,440 shares, expiring June 1, 2018.
	Line of Credit
	On November 19, 2013, we received $50,000 pursuant to a line of credit which accrues interest at a rate of 24%. We have pledged our inventory and accounts receivable as collateral. The maturity date of the line of credit is May 15, 2015.
	For the three-month period ended March 31, 2014 and 2015 we recorded $61,328 and $32,646 of interest expense related to this note, line of credit and convertible notes payable.

Note_6_Conversion_of_Notes

Note 6 - Conversion of Notes	3 Months Ended
	Mar. 31, 2015
Conversion Of Notes [Abstract]
Conversion Of Notes [Text Block]	Note 6. Conversion of Notes
	On March 26, 2014, we issued an aggregate 1,360,000 shares of our common stock, at a conversion price of $0.25, resulting in a fair value of $584,800, as payment for an aggregate $275,000 in principal and $65,000 of accrued and unpaid interest expense for three promissory notes (originally issued on June 8, 2010, October 28, 2013, and November 15, 2013). Our stock price on the date of issuance was $0.43 per share, resulting in an additional financing costs of $244,800 which was recorded as interest expense during the three-month period ended March 31, 2014.

Note_7_Warrants

Note 7 - Warrants	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Warrants [Text Block]	Note 7. Warrants
	We have certain warrants outstanding to purchase our common stock, at various prices, as summarized in the following tables:
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2013		10,618,771		$0.13	-	1
	Issued		3,276,667			0.3
	Expired		(3,506,306	)	0.5	-	1
	Outstanding as of March 31, 2014		10,389,132		$0.13	-	1
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2014		8,838,122		$0.13	-	1
	Issued		1,501,900		0.3	-	0.75
	Expired		—			—
	Outstanding as of March 31, 2015		10,340,022		$0.13	-	1
	The fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows for the three-month periods ended March 31:
		2014			2015
	Risk free interest rate		0.11	%		0.97	-	1.46	%
	Expected volatility		171	%				332	%
	Expected dividend yield		—					—
	Forfeiture rate		—					—
	Expected life in years		0.5					5
	The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock.
	We recorded $244,800 and $72,578 of interest expense related to the amortization of the discount on convertible notes, for the extension of warrants set to expire, and for the fair value of warrants issued for services during the three-month period ended March 31, 2014 and 2015, respectively.
	Warrants Issued Concurrently with Convertible Note Payables
	During the three-month period ended March 31, 2015 we issued warrants to purchase an aggregate 266,000 shares of our common stock. These warrants are exercisable at $0.30 per share and expire January 2020. The fair value of warrants issued in the three-month period ended March 31, 2015 resulted in $133,000 discount on the note payables.
	2015 Unit Offering Warrants
	Pursuant to the terms of our 2015 Unit Offering (see Note 4), during the three-month period ended March 31, 2015, we issued warrants to purchase up to an aggregate 1,023,400 shares of our common stock at an exercise price of $0.40 per share. These warrants were issued to investors and as commissions, and are set to expire June 1, 2020.
	Summer 2013 Warrants
	Pursuant to the terms of our Summer 2013 Offering (see Note 4), since inception in June 2013 through its termination on March 31, 2014, we issued warrants to purchase up to an aggregate 3,370,000 shares of our common stock to the investors in the Summer 2013 Offering at an exercise price of $0.30 per share. Of this amount, we issued warrants to purchase up to an aggregate 3,110,000 shares of our common stock during the three-month period ended March 31, 2014. These warrants are set to expire October 15, 2015.
	Clyra 2014 Warrants
	Pursuant to the terms of the Clyra 2014 Spring Offering (see Note 4), during the three-month period ended March 31, 2014, we issued warrants to purchase up to an aggregate 166,667 shares of our common stock to the investors in the Clyra 2014 Spring Offering at an exercise price of $0.55. These warrants are set to expire July 30, 2015.

Note_8_Stockholders_Equity

Note 8 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8. Stockholders’ Equity
	Preferred Stock
	Our certificate of incorporation authorizes our Board of Directors to issue preferred stock, from time to time, on such terms and conditions as they shall determine. As of December 31, 2014 and March 31, 2015 there were no outstanding shares of our preferred stock.
	Common Stock
	As of December 31, 2014 and March 31, 2015 there were 82,909,300 and 83,322,039 shares of common stock outstanding, respectively. The increase in shares during the three-month period ended March 31, 2015 is comprised of the following stock issuances: (i) 281,978 shares of our common stock issued to officers as payment for accrued and unpaid salary obligations, (ii) 100,000 shares as of our common stock in exchange for shares of our subsidiary Clyra pursuant to the warrant issued in Clyra’s private securities offering, and (iii) 30,761 shares of our common stock to third-party vendors for services performed.

Note_9_StockBased_Compensation

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Compensation and Employee Benefit Plans [Text Block]	Note 9. Stock-Based Compensation and Other Employee Benefit Plans
	2007 Equity Incentive Plan
	Activity for our stock options under the 2007 Plan for the three-month periods ended March 31, 2014 and 2015 is as follows:
												Weighted
	Balance, March 31, 2014:											Average
		Options			Shares			Exercise				Price per
		Outstanding			Available			Price per share				share
	Balances as of December 31, 2013		8,561,086			4,420,742		$0.23	—	1.89		$	0.44
	Granted		—			—			—				—
	Exercised		—			—			—				—
	Expired		—			—			—				—
	Balance, March 31, 2014		8,561,086			4,420,742		$0.23	—	1.89		$	0.44
												Weighted
	Balance, March 31, 2015:											Average
		Options			Shares			Exercise				Price per
		Outstanding			Available			Price per share				share
	Balances as of December 31, 2014		8,601,086			4,380,742		$0.23	—	1.89		$	0.44
	Granted		—			—			—				—
	Exercised		—			—			—				—
	Expired		(200,000	)		—			0.58				0.58
	Balance, March 31, 2015		8,401,086			4,380,742		$0.23	—	1.89		$	0.43
	Options issued Outside of the 2007 Equity Incentive Plan
	During the three-month periods ended March 31, 2014 and 2015 we recorded an aggregate $156,711 and $255,625 in selling general and administrative expense related to stock options issued outside of the 2007 Plan.
	On March 30, 2015, we issued options to purchase 190,142 shares of our common stock at an exercise price of $0.355 per share to our members of our board of directors, in lieu of $45,000 in accrued and unpaid fees due for their services on the board. The fair value of these options totaled $68,451, resulting in $23,451 of additional selling, general and administrative expenses.
	On March 31, 2015, we issued options to purchase 387,676 shares of our common stock at an exercise price of $0.355 per share to two vendors, in lieu of $91,750 in accrued and unpaid fees. The fair value of these options totaled $137,625, resulting in $45,875 of additional selling, general and administrative expenses.
	On March 31, 2014, we issued options to purchase 156,888 shares of our common stock at an exercise price of $0.43 per share to our board of directors, in lieu of $45,000 in accrued and unpaid fees due for their services on the board. The fair value of the Options totaled $67,461, resulting in $22,461 of additional selling, general and administrative expenses.
	On March 31, 2014, we issued Options to purchase 78,488 shares of our common stock at an exercise price of $0.43 per share to a vendor, in lieu of $22,500 in accrued and unpaid fees. The fair value of the Options totaled $33,750, resulting in $11,250 of additional selling, general and administrative expenses.
	Activity of our stock options issued outside of the 2007 Plan for the three-month periods ended March 31, 2014 and 2015 is as follows:
									Weighted
	Balance, March 31, 2014:								Average
		Options			Exercise				Price per
		Outstanding			Price per share				share
	Balance, December 31, 2013		16,398,395		$0.18	-	1		$	0.41
	Granted		235,376			0.43				0.43
	Exercised		—			-				—
	Expired		—			-				—
	Balance, March 31, 2014		16,633,771		$0.18	-	1.00		$	0.39
									Weighted
	Balance, March 31, 2015:								Average
		Options			Exercise				Price per
		Outstanding			Price per share				share
	Balance, December 31, 2014		17,965,291		$0.18	-	1		$	0.4
	Granted		577,818			0.36				0.36
	Exercised		—			-				—
	Expired		—			-				—
	Balance, March 31, 2015		18,543,109		$0.18	-	1.00		$	0.4
	We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the three-month periods ended March 31, 2014 and 2015:
		2014						2015
		Non Plan			2007 Plan			Non Plan			2007 Plan
	Risk free interest rate		2.73	%		—			1.97	%		—
	Expected volatility		935	%		—			821	%		—
	Expected dividend yield		—			—			—			—
	Forfeiture rate		—			—			—			—
	Expected life in years		7			—			7			—
	Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.
	The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future.
	Historically, we have not had significant forfeitures of unvested stock options granted to employees and Directors. A significant number of our stock option grants are fully vested at issuance or have short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

Note_10_Accounts_Payable_and_A

Note 10 - Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 10. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses included the following:
		December 31,		March 31,
		2014		2015
	Accounts payable and accrued expenses	$	313,286	$	312,392
	Contingent liability		137,500		137,500
	Accrued interest		32,256		56,445
	Officer and board of director payables		11,896		5,787
	Total Accounts Payable and Accrued Expenses	$	494,938	$	512,124

Note_11_Noncontrolling_Interes

Note 11 - Noncontrolling Interest	3 Months Ended
	Mar. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	Note 11. Noncontrolling Interest
	In May 2012, we formed a subsidiary for the purpose of marketing and selling medical products containing our technology, Clyra Medical Technologies, Inc. (“Clyra”). Until December 17, 2012, this subsidiary was wholly owned, with 7,500 shares issued to BioLargo, Inc. On December 17, 2012, Clyra signed executive employment agreements with three individuals, in which each was granted 500 shares of Clyra common stock, one-third of which vested immediately, and the remaining over time. The shares granted to the three executives are restricted from transfer until a sale of the company, whether by means of a sale of its stock or substantially all of its assets, or otherwise by agreement of Clyra, BioLargo and the executives.
	Clyra raised $50,000 in proceeds through issuing 50 shares of its common stock during the three-month period ended March 31, 2014. See Note 4. The holdings of the executive officers and investors represented 19.9% of the issued and outstanding stock of the company as of March 31, 2015.
	From inception, Clyra has generated no revenues and the financial impact of Clyra’s operations for the three-month period ended March 31, 2015, resulted in a net loss of $28,965.

Note_12_Subsequent_Events

Note 12 - Subsequent Events.	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12. Subsequent Events.
	Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure.
	2015 Unit Offering
	Subsequent to March 31, 2015, we received $105,000 and issued convertible promissory notes with a maturity date in June 1, 2018 to three investors in our 2015 Unit Offering (see Note 4). Each investor, for no additional consideration, received a stock purchase warrant exercisable at $0.40 per share, which expires June 1, 2020. We issued warrants to purchase an aggregate 420,000 shares.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Inventory, Policy [Policy Text Block]	Inventory
	Inventories are stated at the lower of cost or net realizable value using the average cost method.  Inventories consisted of:
			31-Dec-14		31-Mar-15
	Raw materials		$	18,816	$	18,875
	Finished goods (see Note 4)			6,698		1,640
	Total inventory		$	25,514	$	20,515
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Other Assets
	Other Assets consists of payments made to purchase patents related to our efforts in commercializing the ISAN system.
	For the three-month periods ended March 31, 2014 and 2015 we recorded amortization expense totaling $2,730 and $2,730, respectively.
	We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. No impairment has been recorded for the three-month period ended March 31, 2015.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, uncollectible accounts receivable, asset depreciation and amortization, and taxes, among others.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based Payments
	All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values.
	For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
	During the three-month periods ended March 31, 2014 and 2015 we recorded an aggregate $156,711 and $255,625 in selling general and administrative expense related to options issued outside of our 2007 Equity Incentive Plan (see Note 9).
	During the three-month period ended March 31, 2014 we issued an aggregate 83,493 shares of our common stock to our corporate Secretary/President of our Odor-No-More subsidiary in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $35,902. During the three-month period ended March 31, 2015 we issued an aggregate 281,978 shares of our common stock to our Chief Executive Officer, Chief Technology Officer and our corporate Secretary in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $100,102. (See Note 9).
	During the three-month periods ended March 31, 2014 and 2015 we issued an aggregate 161,980 and 30,761 shares of our common stock to third party vendors in lieu of accrued and unpaid obligations totaling $56,295 and $10,725, respectively. (See Note 9).
Non-Cash Transactions [Policy Text Block]	Non-Cash Transactions
	We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
	The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property or in the form of a grant. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. Grants received are recognized as revenue when the terms and conditions of the grant are met on a periodic basis over the life of the grant.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share
	We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three-month periods ended March 31, 2014 and 2015, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss.
Deferred Charges, Policy [Policy Text Block]	Deferred Financing Fees
	The Company has unamortized debt issuance costs related to its current convertible notes payable and long-term convertible notes payable. These costs are amortized over the life of the related debt and recorded as interest expense. For the three-month period ended March 31, 2015 we had a total of $56,873 of debt issuance costs and amortization totaled $1,456.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new, principle-based revenue recognition framework that will affect all revenue-generating activities. In addition to superseding and replacing nearly all existing revenue recognition guidance under U.S. GAAP, including industry-specific guidance, the new standard:
	•	changes the basis for deciding when revenue is recognized over time or at a point in time;
	•	provides new guidance on specific aspects of revenue recognition; and
	•	expands and improves disclosures about revenue.
	Entities are required to apply the standard for annual periods beginning after December 15, 2017, and for interim periods therein. The standard permits the use of either the retrospective method, where prior period results are reflected on a comparable basis, or cumulative effect method. Management is currently evaluating the effect of this pronouncement on its financial reporting.
	In August 2014, the FASB issued ASU No. 2014-15 ("ASU 2014-15"), Presentation of Financial Statements-Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires a Company's management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its consolidated financial statements.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Inventory, Current [Table Text Block]		31-Dec-14		31-Mar-15
	Raw materials	$	18,816	$	18,875
	Finished goods (see Note 4)		6,698		1,640
	Total inventory	$	25,514	$	20,515

Note_7_Warrants_Tables

Note 7 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Number of
		Shares			Price Range
	Outstanding as of December 31, 2013		10,618,771		$0.13	-	1
	Issued		3,276,667			0.3
	Expired		(3,506,306	)	0.5	-	1
	Outstanding as of March 31, 2014		10,389,132		$0.13	-	1
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2014		8,838,122		$0.13	-	1
	Issued		1,501,900		0.3	-	0.75
	Expired		—			—
	Outstanding as of March 31, 2015		10,340,022		$0.13	-	1
Schedule of Assumptions Used to Determine Fair Value of Warrants [Table Text Block]		2014			2015
	Risk free interest rate		0.11	%		0.97	-	1.46	%
	Expected volatility		171	%				332	%
	Expected dividend yield		—					—
	Forfeiture rate		—					—
	Expected life in years		0.5					5

Note_9_StockBased_Compensation1

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		2014						2015
		Non Plan			2007 Plan			Non Plan			2007 Plan
	Risk free interest rate		2.73	%		—			1.97	%		—
	Expected volatility		935	%		—			821	%		—
	Expected dividend yield		—			—			—			—
	Forfeiture rate		—			—			—			—
	Expected life in years		7			—			7			—
2007 Equity Incentive Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]												Weighted
	Balance, March 31, 2014:											Average
		Options			Shares			Exercise				Price per
		Outstanding			Available			Price per share				share
	Balances as of December 31, 2013		8,561,086			4,420,742		$0.23	—	1.89		$	0.44
	Granted		—			—			—				—
	Exercised		—			—			—				—
	Expired		—			—			—				—
	Balance, March 31, 2014		8,561,086			4,420,742		$0.23	—	1.89		$	0.44
												Weighted
	Balance, March 31, 2015:											Average
		Options			Shares			Exercise				Price per
		Outstanding			Available			Price per share				share
	Balances as of December 31, 2014		8,601,086			4,380,742		$0.23	—	1.89		$	0.44
	Granted		—			—			—				—
	Exercised		—			—			—				—
	Expired		(200,000	)		—			0.58				0.58
	Balance, March 31, 2015		8,401,086			4,380,742		$0.23	—	1.89		$	0.43
Outside of 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]									Weighted
	Balance, March 31, 2014:								Average
		Options			Exercise				Price per
		Outstanding			Price per share				share
	Balance, December 31, 2013		16,398,395		$0.18	-	1		$	0.41
	Granted		235,376			0.43				0.43
	Exercised		—			-				—
	Expired		—			-				—
	Balance, March 31, 2014		16,633,771		$0.18	-	1.00		$	0.39
									Weighted
	Balance, March 31, 2015:								Average
		Options			Exercise				Price per
		Outstanding			Price per share				share
	Balance, December 31, 2014		17,965,291		$0.18	-	1		$	0.4
	Granted		577,818			0.36				0.36
	Exercised		—			-				—
	Expired		—			-				—
	Balance, March 31, 2015		18,543,109		$0.18	-	1.00		$	0.4

Note_10_Accounts_Payable_and_A1

Note 10 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		December 31,		March 31,
		2014		2015
	Accounts payable and accrued expenses	$	313,286	$	312,392
	Contingent liability		137,500		137,500
	Accrued interest		32,256		56,445
	Officer and board of director payables		11,896		5,787
	Total Accounts Payable and Accrued Expenses	$	494,938	$	512,124

Note_1_Business_and_Organizati1

Note 1 - Business and Organization (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Disclosure Text Block [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	($786,188)	($1,073,070)
Net Assets	-529,152
Assets, Current	300,387		230,591
Retained Earnings (Accumulated Deficit)	-79,794,105		-79,019,719
Cash and Cash Equivalents, at Carrying Value	227,441	363,373	154,460	92,437
Revenues	26,671	9,287
Long-term Debt, Gross	613,000
Accounts Payable and Accrued Liabilities, Current	$512,124		$494,938

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)	30,761
Debt Issuance Cost	$56,873
Amortization of Financing Costs	1,456
Selling, General and Administrative Expenses [Member] | 2007 Plan [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Allocated Share-based Compensation Expense	2,730	2,730
Selling, General and Administrative Expenses [Member] | Outside of the 2007 Plan [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Allocated Share-based Compensation Expense	255,625	156,711
Three Executive Officers [Member] | Accrued and Unpaid Salary and Unreimbursed Expenses [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)		83,493
Stock Issued During Period, Value, Other	100,102	35,902
Stock Issued During Period, Shares, Issued for Services (in Shares)	281,978
Third-Party Vendors [Member] | Accrued and Unpaid Salary and Unreimbursed Expenses [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Allocated Share-based Compensation Expense	10,725	56,295
Stock Issued During Period, Value, Issued for Services	30,761	161,980
Patents [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Impairment of Intangible Assets, Finite-lived	$0

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Inventories (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$18,875	$18,816
Finished goods (see Note 4)	1,640	6,698
Total inventory	$20,515	$25,514

Note_3_Deposit_Details

Note 3 - Deposit (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 27, 2015	Mar. 31, 2015	Dec. 31, 2012	Dec. 31, 2014	Feb. 28, 2014
Note 3 - Deposit (Details) [Line Items]
Customer Deposits, Current		$150,000		$100,000
Proceeds from Other Deposits	50,000
Clarion Water [Member] | Beginning July 1, 2016 [Member] | Isan System License Agreement [Member] | Peter Holdings Ltd. [Member] | Licensing Agreements [Member]
Note 3 - Deposit (Details) [Line Items]
Quarterly Payments from Licensee		50,000
Clarion Water [Member] | Isan System License Agreement [Member] | Peter Holdings Ltd. [Member] | Licensing Agreements [Member]
Note 3 - Deposit (Details) [Line Items]
Customer Deposits, Current					$100,000
Royalty as Percentage of Sales		10.00%
Royalty as Percentage of Sublicensing Fees		40.00%
Peter Holdings Ltd. [Member]
Note 3 - Deposit (Details) [Line Items]
Joint Venture, Royalties, Percentage			50.00%

Note_4_Private_Securities_Offe1

Note 4 - Private Securities Offerings (Details) (USD $)	0 Months Ended	9 Months Ended	3 Months Ended	0 Months Ended	12 Months Ended
	Jan. 15, 2015	Mar. 31, 2014	Mar. 31, 2014	Feb. 02, 2014	Dec. 31, 2014	Mar. 31, 2015	Jan. 31, 2015	Mar. 26, 2014
Note 4 - Private Securities Offerings (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$0.40
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$0.25
Common Stock, Shares Authorized (in Shares)					200,000,000	200,000,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%					12.00%
Warrant Term	30 days
Summer 2014 Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)		$0.25	$0.25
Stock Issued During Period, Shares, New Issues (in Shares)		3,370,000
Summer 2013 [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)			3,110,000
Proceeds from Issuance of Private Placement		$842,500	$777,500
Proceeds from Issuance of Private Placement Net		837,000
Payments of Stock Issuance Costs			5,500
Accrued Private Placement Fees			47,100
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						0.3
Debt Instrument, Convertible, Conversion Price (in Dollars per share)						0.6
Clyra Spring 2014 Private Securities Offering [Member] | Common Stock [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$1,833.33
Warrant Number of Parent Shares Received for One Share of Subsidiary (in Shares)				4,000
Clyra Spring 2014 Private Securities Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)				$1,000
Stock Issued During Period, Shares, New Issues (in Shares)				50
Proceeds from Issuance of Private Placement				50,000
Common Stock, Shares Authorized (in Shares)				1,000
2015 Unit Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Over-Allotment Percentage	20.00%
Maximum Over-Allotment Amount	1,000,000
Unit Offering Maximum Value	6,000,000
Minimum Proceeds Required for Stock Registration	3,000,000
2015 Unit Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$0.30	0.3
Maximum Discount on Securities Offering	30.00%
Debt Instrument, Interest Rate, Stated Percentage					12.00%	12.00%
Warrant Term					3 years

Note_5_Notes_and_Convertible_N1

Note 5 - Notes and Convertible Notes Payable (Details) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 15, 2015	Nov. 19, 2013	Mar. 26, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jan. 31, 2015	Apr. 27, 2015
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Proceeds from Issuance of Debt				$230,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%			12.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							1,023,400
				258,071		192,000	230,000
Warrant Term	30 days
Proceeds from Lines of Credit		50,000
Line of Credit Facility, Interest Rate at Period End		24.00%
Interest Expense, Debt			65,000	32,646	61,328
Subsequent Event [Member] | 2015 Unit Offering [Member]
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)								226,440
2015 Unit Offering [Member]
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				12.00%		12.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$0.30		$0.30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)				266,000		350,000
				133,000		200,000
Debt Instrument, Term				3 years
Debt Instrument, Face Amount						$200,000
Warrant Term						3 years

Note_6_Conversion_of_Notes_Det

Note 6 - Conversion of Notes (Details) (USD $)	1 Months Ended	3 Months Ended
	Mar. 26, 2014	Mar. 31, 2015	Mar. 31, 2014
Conversion Of Notes [Abstract]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,360,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$0.25
Stock Issued During Period, Value, Conversion of Convertible Securities	$584,800
Debt Conversion, Converted Instrument, Amount	275,000
Interest Expense, Debt	65,000	32,646	61,328
Share Price (in Dollars per share)	$0.43
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$244,800

Note_7_Warrants_Details

Note 7 - Warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2015	Dec. 31, 2014
Note 7 - Warrants (Details) [Line Items]
Amortization of Debt Discount (Premium) (in Dollars)	$72,578	$244,800
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,023,400
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$0.40
(in Dollars)	258,071		230,000	192,000
Conversion of Notes Payables [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	266,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.30
(in Dollars)	$133,000
2015 Unit Offering [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,023,400
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.40
Summer 2013 [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,370,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$0.30
Stock Issued During Period, Shares, New Issues		3,110,000
Clyra Spring 2014 Private Securities Offering [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		166,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$0.55

Note_7_Warrants_Details_Warran

Note 7 - Warrants (Details) - Warrants Outstanding (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Number of Shares (in Shares)	10,340,022	10,389,132	8,838,122	10,618,771
Shares Issued (in Shares)	1,501,900	3,276,667
Issued Price Range		$0.30
Shares Expired (in Shares)		-3,506,306
Minimum [Member]
Class of Warrant or Right [Line Items]
Price Range	0.125	$0.13	0.125	0.125
Issued Price Range	0.3
Expired Price Range		$0.50
Maximum [Member]
Class of Warrant or Right [Line Items]
Price Range	1	$1	1	1
Issued Price Range	0.75
Expired Price Range		$1

Note_7_Warrants_Details_Assump

Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants (Warrant [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate		0.11%
Expected volatility		171.00%
Expected life in years		6 months
Minimum [Member]
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate	0.97%
Maximum [Member]
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate	1.46%
Expected volatility	332.00%
Expected life in years	5 years

Note_8_Stockholders_Equity_Det

Note 8 - Stockholders' Equity (Details)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note 8 - Stockholders' Equity (Details) [Line Items]
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares, Outstanding	83,322,039	82,909,300
Stock Issued During Period, Shares, Issued for Services	30,761
Clyra [Member]
Note 8 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	100,000
Accrued and Unpaid Salary and Unreimbursed Expenses [Member]
Note 8 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	281,978

Note_9_StockBased_Compensation2

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) (USD $)	3 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2014
Employee Stock Option [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate	0.00%
Selling, General and Administrative Expenses [Member] | Board of Directors [Member] | Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Allocated Share-based Compensation Expense	23,451	$22,461
Selling, General and Administrative Expenses [Member] | Vendors [Member] | Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Allocated Share-based Compensation Expense	45,875	11,250
Selling, General and Administrative Expenses [Member] | Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Allocated Share-based Compensation Expense	255,625		156,711
Board of Directors [Member] | Outside of the 2007 Plan [Member] | Accrued and Unpaid Obligations [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Other Liabilities, Current	45,000	45,000	45,000
Board of Directors [Member] | Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	190,142
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	0.355
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	68,451	67,461
Board of Directors [Member] | Accrued and Unpaid Obligations [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)			156,888
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)			$0.43
Vendors [Member] | Outside of the 2007 Plan [Member] | Accrued and Unpaid Obligations [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Other Liabilities, Current	91,750	22,500	22,500
Vendors [Member] | Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	387,676	78,488
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	0.355	$0.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	137,625	$33,750
Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	577,818		235,376
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	0.36		$0.43

Note_9_StockBased_Compensation3

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Options Outstanding (in Shares)	8,401,086	8,601,086	8,561,086	8,561,086
Shares Available (in Shares)	4,380,742	4,380,742	4,420,742	4,420,742
Average Price per Share	$0.43	$0.44	$0.44	$0.44
Options Expired (in Shares)	-200,000
Exercise Price per Share, Expired	$0.58
Average Price per Share, Expired	$0.58
Minimum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Exercise Price per Share	$0.23	$0.23	$0.23	$0.23
Maximum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Exercise Price per Share	$1.89	$1.89	$1.89	$1.89

Note_9_StockBased_Compensation4

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Options Outstanding (in Shares)	8,401,086	8,561,086	8,601,086	8,561,086
Weighted Average Price per Share	$0.43	$0.44	$0.44	$0.44
Outside of the 2007 Plan [Member] | Minimum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share	$0.18	$0.18	$0.18	$0.18
Outside of the 2007 Plan [Member] | Maximum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share	$1	$1	$1	$1
Outside of the 2007 Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Options Outstanding (in Shares)	18,543,109	16,633,771	17,965,291	16,398,395
Weighted Average Price per Share	$0.40	$0.39	$0.40	$0.41
Options Granted (in Shares)	577,818	235,376
Exercise Price per Share, Granted	$0.36	$0.43
Weighted Average Price per Share, Granted	$0.36	$0.43
Minimum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share	$0.23	$0.23	$0.23	$0.23
Maximum [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share	$1.89	$1.89	$1.89	$1.89

Note_9_StockBased_Compensation5

Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions (Non Plan [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Non Plan [Member]
Note 9 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate	1.97%	2.73%
Expected volatility	821.00%	935.00%
Expected life in years	7 years	7 years

Note_10_Accounts_Payable_and_A2

Note 10 - Accounts Payable and Accrued Expenses (Details) - Accounts Payable and Accrued Expenses (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable and accrued expenses	$312,392	$313,286
Contingent liability	137,500	137,500
Accrued interest	56,445	32,256
Officer and board of director payables	5,787	11,896
Total Accounts Payable and Accrued Expenses	$512,124	$494,938

Note_11_Noncontrolling_Interes1

Note 11 - Noncontrolling Interest (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 17, 2012	31-May-12
Note 11 - Noncontrolling Interest (Details) [Line Items]
Sale of Stock, Percentage of Ownership after Transaction		19.90%
Revenues	$26,671	$9,287
Net Income (Loss) Attributable to Noncontrolling Interest	-5,756	-53,684
Each of 3 Individuals [Member] | Clyra Medical Technology, Inc. [Member]
Note 11 - Noncontrolling Interest (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			500
Clyra Medical Technology, Inc. [Member]
Note 11 - Noncontrolling Interest (Details) [Line Items]
Investment Owned, Balance, Shares				7,500
Stock Issued During Period, Value, New Issues		50,000
Sale of Stock, Number of Shares Issued in Transaction		50
Revenues	0
Net Income (Loss) Attributable to Noncontrolling Interest	$28,965

Note_12_Subsequent_Events_Deta

Note 12 - Subsequent Events. (Details) (USD $)	0 Months Ended
	13-May-15	Jan. 31, 2015	Mar. 31, 2015
Note 12 - Subsequent Events. (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,023,400
Subsequent Event [Member] | 2015 Unit Offering [Member]
Note 12 - Subsequent Events. (Details) [Line Items]
Proceeds from Convertible Debt	$105,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.40
Subsequent Event [Member] | 2015 Unit Offering [Member]
Note 12 - Subsequent Events. (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	420,000
2015 Unit Offering [Member]
Note 12 - Subsequent Events. (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,023,400